NZ's PHARMAC considers listing of Amgen's Sensipar

11 March 2016

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list cinacalcet (Sensipar) on the Pharmaceutical Schedule through a provisional agreement with the local subsidiary of US biotech major Amgen (Nasdaq: AMGN) from May 1, 2016 for:

patients with parathyroid carcinoma with symptomatic hypercalcemia resistant to bisphosphonates and sodium thiosulfate, subject to Special Authority criteria;
patients with symptomatic calciphylaxis after failure of bisphosphonates and sodium thiosulfate, subject to Special Authority criteria.

Cinacalcet (Sensipar) 30 mg tablets would be listed in Section B and Part II of Section H of the Pharmaceutical Schedule from May 1, 2016 at a price of NZ403.70 per 28 30mg tablets.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK